We read with great interest the original work by Murphy et al analyzing the effects of two
treatment strategies for delivery of noninvasive mechanical ventilation in hypercapnic patients with
chronic obstructive pulmonary disease.1 High
pressure and high intensity noninvasive mechanical ventilation were compared in a short-term
crossover trial to assess whether high intensity noninvasive mechanical ventilation (inspiratory
pressure > 25 cm H2O associated with a high backup ventilator rate) may improve
adherence, physiological, and subjective outcomes when compared with delivery of high pressure
noninvasive mechanical ventilation (without elevated backup respiratory rate). The authors concluded
that both strategies are equivalent in all the recorded outcomes, showing thus that driving
pressure, but not backup respiratory rate, is essential to gain physiological and clinical benefits
in this population when in a chronic stable condition.Despite previous randomized studies showing the potential benefits of long-term noninvasive
mechanical ventilation in hypercapnic patients with chronic obstructive pulmonary disease, current
research has still not clearly indicated the best strategy to improve the patient’s
adherence with treatment.2,3 Overall, dropout during noninvasive mechanical ventilation remains a
serious clinical problem.4 This study provides
valuable information in this regard, suggesting that sufficiently high-pressure delivery is enough
to achieve useful clinical and physiological goals.This notwithstanding, we believe that some of the expectations following the adoption of these
different noninvasive mechanical ventilation strategies have not been adequately addressed in the
present study. Therefore, we consider that it would be useful, from a practical point of view, to
underline some points in this regard.First, the authors did not determine what effects the highest respiratory backup rate used in
their study may have had. Although there have been no major studies published on application of high
levels of backup that have proved to be useful in patients with severe chronic obstructive pulmonary
disease, this is the best indication for hypoventilation syndromes, ie, obesity and overlap
syndromes. In fact, we cannot exclude that addition of a high backup respiratory rate may help to
resolve “overlap” when present at a subclinical level in patients with chronic
obstructive pulmonary disease, or that it has not been adequately assessed before. However, it seems
that the authors selected backup respiratory rate levels on a clinical basis without any
physiological assessment in their study population. Despite patients in the present study not
appearing to show any abnormal increase in their body mass index, the extrapolated conclusion of a
lack of additional benefit from a well assessed strategy, including adequate backup respiratory
rate, cannot be firmly excluded in such “extreme” cases.5Second, there was a lack of complementary tests in this study that might have helped in analysis
of the data. Indeed, the authors selected patients with a FEV1 (forced expiratory volume
in one second) that could worsen with high backup and pressure, especially with the auto-positive
end-expiratory pressure mechanism. It is not clear how selection of expiratory-positive airway
pressure was made in the study population. Similarly, the authors did not take into account any
potential auto-positive end-expiratory pressure effects during the 6-week period of observation.Third, the authors arbitrarily selected a population of hypercapnic patients with chronic
obstructive pulmonary disease (daytime PaCO2 > 6 kPa) which would not be
universally recognized as the most appropriate in terms of risk of frequency of exacerbations and
clinical instability, and it is not clear whether any other additional clinical factors behind
cardiac dysfunction may have interfered at admission or over the study period.6 Indeed, three of the five patients who withdrew did so because of
factors other than mere mask/pressure intolerance (see Table E1).1Final, there was no analysis of potential implications of air leakage in the observed results. No
mention was made of measurement or monitoring of leakage during application of noninvasive
mechanical ventilation. This aspect could have been potentially relevant and interfered with the
results, especially during application of such high-pressure delivery, which is known to increase
mask leakages.4To conclude, we recognize that the paper by Murphy et al1 will add information to the complex process of setting and titration of noninvasive
mechanical ventilation in the population of stable hypercapnic patients with chronic obstructive
pulmonary disease. However, given the observations discussed, we are convinced that further studies
of longer duration and including larger numbers of patients are needed to determine which
physiological effects should be assessed and expected during application of both strategies.
Currently, high-pressure strategies remain a “double edged sword” in daily
practice.We thank Esquinas et al for their thoughtful comments on our recent published trial. We
acknowledge that the set backup rate in the high-intensity group was determined clinically. However,
the low triggering rate recorded in the high-intensity arm indicates that these patients were
largely in mandatory ventilation, ie, by definition, they received high-intensity ventilation.
Further, we consider that the high backup rate would be expected to contribute further to intrinsic
positive end-expiratory pressure because the lung emptying at the end of expiration would be
incomplete as the ventilator cycles from expiration to inspiration early, which would contribute
greater patient-ventilator asynchrony. Patients with obstructive sleep apnea and/or obesity
hypoventilation syndrome were excluded from the study because this is the group most likely to
benefit from addition of a backup rate, a point highlighted by Esquinas et al. In a post hoc
analysis of another recently published trial, a backup rate of 14 breaths per minute in obesepatients was more important in controlling nocturnal hypoventilation than the mode of ventilation
per se.1The expiratory-positive airway pressure setting in the study was selected according to the
ventilation setup algorithm provided in Figure E1.2
The major clinical drive to undertake this trial was a physiological concern that use of
high-intensity noninvasive mechanical ventilation in chronic obstructive pulmonary disease would
exacerbate intrinsic positive end-expiratory pressure and subsequently have an adverse effect on
outcome. Although the high-intensity mode has been shown to provide superior control of nocturnal
hypoventilation compared with the low-intensity mode,3 it has not been compared with a high-pressure strategy alone until the current published
trial. The authors considered that this would have a lesser impact on patient-ventilator asynchrony,
although we acknowledge that we did not make detailed physiological measurements in this randomized,
controlled clinical trial. However, the expected adverse clinical impact of intrinsic positive
end-expiratory pressure would be a worsening of patient-ventilator synchrony, and this would be
reflected in a reduction in patient subjective or objective assessment of sleep, recorded in the
study by visual analog score and actigraphy, respectively. Neither marker indicated a treatment
effect in the current study. The earlier work by Dreher et al, which compared a high-intensity
versus low-intensity approach, again failed to show a difference in subjective or objective sleep
during application of noninvasive mechanical ventilation.4Earlier work using low-pressure strategies has failed to demonstrate unequivocally a clinical
benefit of noninvasive mechanical ventilation in hypercapnic chronic obstructive pulmonary disease
and, as such, there is debate as to the phenotype of patient that will benefit most from domiciliary
noninvasive mechanical ventilation. Thus, the current inclusion criteria are to some extent
arbitrary, and the selection of patients was clearly described in the methods. Currently, there is a
great deal of interest in which patients benefit most from domiciliary noninvasive mechanical
ventilation, and this is the focus of ongoing European trials (HoT-HMV UK, NCT00990132,
NCT00710541). On a related point, we agree with Esquinas et al that patients with chronic
obstructive pulmonary disease and a significantly elevated PaCO2 are most likely to
benefit, as was shown in the current trial, given that the mean PaCO2 was 8.5 ±
1.8 kPa.Finally, measurements of air leak were not performed in the current trial, and addition of these
data could have enhanced the paper and provided useful information for the clinician when applying
the study conclusions in clinical practice. The authors acknowledge that ventilator settings and
higher pressure may well be associated with higher levels of leak and that these may interfere with
patient-ventilator synchrony and thus adherence with noninvasive mechanical ventilation.5The data from the current study add to the previously published data to allow the clinician
greater scope in the management of these complex and challenging patients. In essence, control of
nocturnal hypoventilation should be the therapeutic goal of noninvasive mechanical ventilation in
chronic obstructive pulmonary disease. The ventilation strategy requires a personalized approach
that is modeled for the individual patient and, as such, the clinician must always remember that
there is “more than one way to skin a cat”.
Authors: Patrick Brian Murphy; Craig Davidson; Matthew David Hind; Anita Simonds; Adrian J Williams; Nicholas S Hopkinson; John Moxham; Michael Polkey; Nicholas Hart Journal: Thorax Date: 2012-03-01 Impact factor: 9.139
Authors: Michael Dreher; Emelie Ekkernkamp; Stephan Walterspacher; David Walker; Claudia Schmoor; Jan H Storre; Wolfram Windisch Journal: Chest Date: 2011-05-12 Impact factor: 9.410
Authors: R D McEvoy; R J Pierce; D Hillman; A Esterman; E E Ellis; P G Catcheside; F J O'Donoghue; D J Barnes; R R Grunstein Journal: Thorax Date: 2009-02-12 Impact factor: 9.139
Authors: Dan Adler; Stephen Perrig; Hiromitsu Takahashi; Fabrice Espa; Daniel Rodenstein; Jean Louis Pépin; Jean-Paul Janssens Journal: Sleep Breath Date: 2011-11-04 Impact factor: 2.816
Authors: Patrick B Murphy; Kate Brignall; John Moxham; Michael I Polkey; A Craig Davidson; Nicholas Hart Journal: Int J Chron Obstruct Pulmon Dis Date: 2012-12-11
Authors: L De Backer; W Vos; B Dieriks; D Daems; S Verhulst; S Vinchurkar; K Ides; J De Backer; P Germonpre; W De Backer Journal: Int J Chron Obstruct Pulmon Dis Date: 2011-11-18